In short
There is currently 1 ongoing clinical trial investigating treatment options for brain abscess. This trial is exploring whether oral antibiotics can be as effective as intravenous antibiotics in treating this serious infection of the brain, offering patients a potentially more convenient treatment approach.
Clinical trial locations
- Denmark
- France
- Netherlands
- Sweden
Study on Oral Antibiotics Moxifloxacin, Linezolid, and Metronidazole for Patients with Bacterial Brain Abscess
This trial is being conducted in Sweden, Netherlands, France, and Denmark and focuses on comparing two different ways of giving antibiotics to treat bacterial brain abscesses. The study aims to find out if antibiotics taken by mouth can work just as well as antibiotics given through a vein, which has traditionally been the standard treatment approach.
Inclusion criteria: To participate in this trial, you must be over 17 years old and have a confirmed diagnosis based on symptoms and brain imaging. Your doctor must have decided to treat you for this condition, and you need to be able to take medicines by mouth. An important requirement is that you must have already received intravenous antibiotics for at least 14 consecutive days before joining the study, with no additional surgical procedures planned. You should also be expected to continue treatment for at least another 14 days, and your neurological condition should be stable, with no worsening symptoms or new problems within 5 days before enrollment.
Exclusion criteria: The trial excludes patients who fall outside the specified age range or those who are considered part of vulnerable populations requiring special protection or care.
Trial focus: The study is designed to evaluate whether oral antibiotics are as effective as intravenous antibiotics in treating this serious infection. Participants will be randomly assigned to receive either oral or intravenous treatment. If you are assigned to the oral group, you may receive medications such as Moxifloxacin, Linezolid, Metronidazole, Clindamycin, or Amoxicillin in tablet or capsule form. If assigned to the intravenous group, you may receive Cefotaxime, Meropenem, or Ceftriaxone through a vein. The treatment continues for at least 14 days after randomization, followed by regular follow-up assessments at the end of treatment and at 3, 6, and 12 months to monitor your recovery and check for any recurrence or complications.
Investigational drugs: The trial tests both oral and intravenous antibiotics. Oral antibiotics work by targeting and killing bacteria or stopping their growth when taken by mouth. Intravenous antibiotics deliver medication directly into the bloodstream, allowing for quick and effective treatment of serious infections. The study aims to determine whether the more convenient oral route can achieve similar results to the traditional intravenous method.
Summary
Currently, there is one active clinical trial investigating treatment options for bacterial brain abscesses. This trial represents an important effort to improve patient care by exploring whether oral antibiotics can replace intravenous antibiotics, which would offer patients a more convenient and potentially less invasive treatment option. The trial is being conducted across multiple European countries, including Sweden, the Netherlands, France, and Denmark, reflecting an international collaborative effort to address this serious condition. The study focuses on several commonly used antibiotics, both oral and intravenous formulations, and includes comprehensive follow-up over 12 months to assess long-term outcomes and safety.
